Jefferies raised the firm’s price target on Liquidia (LQDA) to $31 from $27 and keeps a Buy rating on the shares after the company announced that the FDA has approved Yutrepia inhalation powder for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. While the stock has been trading incrementally lower post approval, the firm thinks investors are “holding their breaths” waiting for a decision in the ‘782 case, noting that the North Carolina judge intends to get a ruling as soon as possible, most likely on the temporary restraining order first.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia Technologies: Overcoming Legal Hurdles with Yutrepia’s FDA Approval and Positive Growth Outlook
- Liquidia price target raised to $25 from $22 at BofA
- Buy Rating for Liquidia Technologies: Strategic Positioning and Market Potential Drive Optimism
- Liquidia Technologies Gains FDA Approval for YUTREPIA
- Liquidia Technologies trading resumes